GSK PLC on Tuesday welcomed a jury verdict in the Joiner case in Illinois state court that found in the drug makers favour.
The jury found GSK not liable for the plaintiff’s colorectal cancer, rejecting the plaintiff’s ability to request punitive damages.
‘This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims,’ London-based company said.
Zantac was a heartburn drug that was pulled off the market in 2020 at the request of the US Food & Drug Administration, after low levels of a ‘probable carcinogen’ were found in samples. The carcinogen, known as NDMA, is not harmful in very small amounts. However, tests showed that there were excessive quantities of NDMA in ranitidine, otherwise known as Zantac. Multiple litigations have followed.
In late June, GSK reached a confidential settlement with Martin Gross resolving the case he filed in Illinois state court regarding Zantac. GSK did not admit any liability in this settlement.
Earlier in June, GSK said a further case in Illinois had been dismissed.
GSK shares were 1.0% lower at 1,532.00 pence each on Tuesday morning in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
